 Rigel Pharmaceuticals Inc. shares soared 39 in premarket trade Thursday, after the company said it has agreed to partner with Eli Lilly and Co. in developing RIPK1 Inhibitors to treat immunological and neurodegenerative diseases. As part of the deal, Rigel will receive an upfront cash payment of 125 million and have the potential to earn up to 835 million in milestone payment on reaching certain goals. 